1174046-72-0 Usage
Description
BMS-794833 is a potent ATP-competitive small molecule inhibitor that targets Met/VEGFR-2 kinase, as well as Ron (Met family), Axl, and Flt-3 with IC50 values less than 3 nM. It is a promising pharmaceutical candidate for various applications due to its ability to inhibit multiple kinases involved in cellular processes.
Uses
Used in Pharmaceutical Industry:
BMS-794833 is used as a therapeutic agent for targeting Met/VEGFR-2 kinase and other related kinases, such as Ron, Axl, and Flt-3. Its application is primarily focused on the treatment of various cancers and diseases where these kinases play a significant role in the development and progression of the disease.
Used in Cancer Research:
BMS-794833 is used as a research tool for studying the role of Met/VEGFR-2 kinase and other related kinases in cancer cell growth, survival, and angiogenesis. It helps researchers understand the molecular mechanisms underlying these processes and identify potential therapeutic targets for cancer treatment.
Used in Drug Development:
BMS-794833 is used as a lead compound in the development of new drugs targeting Met/VEGFR-2 kinase and other related kinases. Its potent inhibitory activity and selectivity make it a valuable starting point for designing and optimizing novel therapeutic agents for cancer and other diseases.
Used in Drug Combination Therapy:
BMS-794833 can be used in combination with other targeted therapies or conventional chemotherapeutic drugs to enhance the treatment efficacy and overcome resistance in cancer patients. Its ability to inhibit multiple kinases involved in cancer progression makes it a suitable candidate for combination therapies.
Biological Activity
bms-794833 is a potent atp competitive, dual inhibitor of c-met and vegfr2 (ic50 = 1.7 nm and 15 nm, respectively). it also has inhibitory effect on ron, axl and flt3 (ic50 < 3 nm).c-met, also called met, is a membrane receptor that is essential for embryonic development and wound healing. vegfr are receptors for vascular endothelial growth factor and belong to receptor tyrosine kinases. it mediates in various cellular functions, including endothelial proliferation, migration, survival, tubular morphogenesis and sprouting. [1]bms794833 also inhibited gastric cancer cell line (gtl-16) that induced by c-met receptor, gtl-16, ic50 = 39 nm [1]. in human gastric tumor xenografts model, bm798433 exhibits > 50% tgi for at least one tumor doubling time without significant toxicity in 14 days. in u87 glioblastoma model, 25mg/kg of bms798433 exert complete tumor stasis. [1]
references
[1] 4-pyridinone compounds and their use of cancer, borzilleri et al, united states patent application publication, pub no. : us 2012/0114643 a1, pub.date: may 10, 2012.
Check Digit Verification of cas no
The CAS Registry Mumber 1174046-72-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,7,4,0,4 and 6 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1174046-72:
(9*1)+(8*1)+(7*7)+(6*4)+(5*0)+(4*4)+(3*6)+(2*7)+(1*2)=140
140 % 10 = 0
So 1174046-72-0 is a valid CAS Registry Number.
1174046-72-0Relevant articles and documents
4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER
-
Page/Page column 27; 37, (2009/09/05)
Disclosed are compounds of Formula (I)and salts thereof. Also, disclosed are methods of using the compounds in the treatment of proliferative diseases, such as cancer, and to pharmaceutical compositions comprising at least one compound of Formula (I) or a
